There is a dire need for novel therapy for brain tumors. Diffuse glioma cell invasion into surrounding brain tissue and angiogenesis are fundamental features of gliomas that have not been successfully addressed by conventional therapy to control tumor growth in brain tumor patients. Current aggressive local treatments such as surgery, radiotherapy and chemotherapy are effective at controlling the localized mass of tumor cells in the brain. This success is only temporary, because tumor cells that have already invaded into the surrounding brain and serve as seeds by which the tumor re-grows. The process by which these tumor cells invade into the brain is not well understood. New treatment approaches that are capable to control these invading tumor cells can have a dramatic impact on patient outcome. We have developed assays in vitro and in vivo that allow us to study invading glioma and endothelial cells. Our long-term goal remains to interfere with tumor invasion and angiogenesis to diminish tumor growth. To this end we propose i) to determine mechanisms involved in the migration of both endothelial and glioma cells; and ii) to investigate the mechanism and therapeutic potential of two geldanamycin analogues on glioma in vitro and in vivo. Our proposal seeks to take advantage of new molecular biologic techniques to improve our understanding of this process. Collectively, the proposed experiments will analyze the cellular and molecular pathways necessary for tumor invasion and angiogenesis. Results from these experiments will lead to future strategies designed to inhibit specific molecular components implicated in these critical processes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA100426-04
Application #
7218651
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Woodhouse, Elizabeth
Project Start
2004-04-01
Project End
2009-02-28
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
4
Fiscal Year
2007
Total Cost
$262,798
Indirect Cost
Name
New York University
Department
Pathology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Haber, Matthew A; Iranmahboob, Amir; Thomas, Cheddhi et al. (2015) ERG is a novel and reliable marker for endothelial cells in central nervous system tumors. Clin Neuropathol 34:117-27
Hardee, Matthew E; Zagzag, David (2012) Mechanisms of glioma-associated neovascularization. Am J Pathol 181:1126-41
Williams, Susan C; Karajannis, Matthias A; Chiriboga, Luis et al. (2011) R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1? upregulation in adult glioma. Acta Neuropathol 121:279-81
Chen, Gregory J; Karajannis, Matthias A; Newcomb, Elizabeth W et al. (2010) Overexpression and activation of epidermal growth factor receptor in hemangioblastomas. J Neurooncol 99:195-200
Mendez, Olga; Zavadil, Jiri; Esencay, Mine et al. (2010) Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer 9:133
Esencay, Mine; Newcomb, Elizabeth W; Zagzag, David (2010) HGF upregulates CXCR4 expression in gliomas via NF-kappaB: implications for glioma cell migration. J Neurooncol 99:33-40
Lu, H; Pollack, E; Young, R et al. (2008) Predicting grade of cerebral glioma using vascular-space occupancy MR imaging. AJNR Am J Neuroradiol 29:373-8
Newcomb, Elizabeth W; Lukyanov, Yevgeniy; Smirnova, Iva et al. (2008) Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway. Anticancer Drugs 19:553-63
Zagzag, David; Esencay, Mine; Mendez, Olga et al. (2008) Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol 173:545-60
Law, Meng; Young, Robert J; Babb, James S et al. (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490-8

Showing the most recent 10 out of 19 publications